Next Article in Journal
A Scoping Review on the Reported Evidence and Gaps of the Risk of Diabetes in Dyslipidemic Patients under Statin Therapy
Previous Article in Journal
Quality in Clinical Consultations: A Cross-Sectional Study
 
 
Article

Association between Empagliflozin Use and Electrocardiographic Changes

1
Department of Internal Medicine, Reno School of Medicine, University of Nevada, Reno, NV 89502, USA
2
Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
3
Department of Internal Medicine, Christus Ochsner Saint Patrick Hospital, Lake Charles, LA 70601, USA
4
Division of Cardiology, Virginia Commonwealth University, Richmond, VA 23219, USA
5
Department of Cardiology, Emory Decatur Hospital, Decatur, GA 30033, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Alberto Cordero and Anna Capasso
Clin. Pract. 2022, 12(4), 557-564; https://doi.org/10.3390/clinpract12040059
Received: 2 June 2022 / Revised: 29 June 2022 / Accepted: 13 July 2022 / Published: 15 July 2022
Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes mellitus. We compared ECG features of 101 patients before and after initiation of empagliflozin and found that empagliflozin was associated with a significant increase in QRS duration among diabetes patients with heart failure. View Full-Text
Keywords: electrocardiography; empagliflozin; heart failure; SGLT2 inhibitors; late sodium channel electrocardiography; empagliflozin; heart failure; SGLT2 inhibitors; late sodium channel
Show Figures

Figure 1

MDPI and ACS Style

Antwi-Amoabeng, D.; Sathappan, S.; Beutler, B.D.; Ulanja, M.B.; Awad, M.; Gullapalli, N.; Duncan, P.; Gbadebo, T.D. Association between Empagliflozin Use and Electrocardiographic Changes. Clin. Pract. 2022, 12, 557-564. https://doi.org/10.3390/clinpract12040059

AMA Style

Antwi-Amoabeng D, Sathappan S, Beutler BD, Ulanja MB, Awad M, Gullapalli N, Duncan P, Gbadebo TD. Association between Empagliflozin Use and Electrocardiographic Changes. Clinics and Practice. 2022; 12(4):557-564. https://doi.org/10.3390/clinpract12040059

Chicago/Turabian Style

Antwi-Amoabeng, Daniel, Sunil Sathappan, Bryce D. Beutler, Mark B. Ulanja, Munadel Awad, Nageshwara Gullapalli, Phillip Duncan, and T. David Gbadebo. 2022. "Association between Empagliflozin Use and Electrocardiographic Changes" Clinics and Practice 12, no. 4: 557-564. https://doi.org/10.3390/clinpract12040059

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop